FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to using matrix metalloproteinase-10 for preparing pharmaceutical combinations applicable for thrombolytic therapy, as well as to pharmaceutical combinations for treating thrombolytic disorders and to a method of thrombolytic therapy. The present combination may also contain a plasminogen activator.
EFFECT: group of inventions provides the alternative therapeutic combinations for thrombolytic therapy which contribute to fibrinolysis by selective degradation of fibrin and help to minimise the adverse effects related to the thrombolytic therapy.
26 cl, 6 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR ANTIFIBRINOLYTIC TREATMENT | 2008 |
|
RU2453337C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIIA AND FACTOR XIII | 2001 |
|
RU2272648C2 |
| METHOD OF PRODUCTION OF PLASMINOGEN ACTIVATOR | 2007 |
|
RU2346983C1 |
| PLASMINOGEN AND PLASMIN VARIANTS | 2012 |
|
RU2604807C2 |
| RECOMBINANT POLYPEPTIDE WITH HUMAN PLASMINOGEN PROPERTIES TO CONVERT INTO PLASMIN IF ACTIVATED WHICH CATALYSES FIBRIN SPLITTING, DNA FRAGMENT CODING POLYPEPTIDE, RECOMBINANT PLASMID DNA FOR POLYPEPTIDE EXPRESSION AND TRANSFORMED Escherichia coli CELL - POLYPEPTIDE PRODUCER | 2009 |
|
RU2432396C2 |
| PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC AND FIBRINOLYTIC EFFECT | 2002 |
|
RU2216348C1 |
| PLASMINOGEN AND PLASMIN VARIANTS | 2012 |
|
RU2604810C2 |
| THROMBOLYTICS FOR INTRAVASCULAR THROMBI | 2020 |
|
RU2822136C1 |
| RECOMBINANT PLASMID DNA pBK415 CODING POLYPEPTIDE OF RECOMBINANT TISSULAR ACTIVATOR OF PLASMINOGEN OF HUMAN BEING, CELL LINE Cricetulus griseus CHO 1F8-PRODUCER OF RECOMBINANT TISSULAR ACTIVATOR OF PLASMINOGEN OF HUMAN BEING, AND METHOD FOR OBTAINING AND SEPARATION OF POLYPEPTIDE HAVING ACTIVITY OF TISSULAR ACTIVATOR OF PLASMINOGEN | 2012 |
|
RU2500817C1 |
| COMBINATION OF THROMBOLYTICALLY ACTIVE PROTEINS AND ANTICOAGULANTS | 1995 |
|
RU2166326C2 |
